.ANALYSIS FEATURE.06 August 2024.
A large randomized controlled trial with cisgender females highlights the challenges of adherence to an everyday oral preexposure treatment program and displays that twice-yearly shot of lenacapavir can easily sustain effective HIV protection degrees over 6 months.